<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27655643</article-id><article-id pub-id-type="pmc">5341934</article-id><article-id pub-id-type="publisher-id">12056</article-id><article-id pub-id-type="doi">10.18632/oncotarget.12056</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Perrone</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Baldassarre</surname><given-names>Gustavo</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Indraccolo</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Signoriello</surname><given-names>Simona</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chiappetta</surname><given-names>Gennaro</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Esposito</surname><given-names>Franca</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ferrandina</surname><given-names>Gabriella</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Franco</surname><given-names>Renato</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A15"><sup>15</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mezzanzanica</surname><given-names>Delia</given-names></name><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sonego</surname><given-names>Maura</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zulato</surname><given-names>Elisabetta</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zannoni</surname><given-names>Gian F.</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Canzonieri</surname><given-names>Vincenzo</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Scambia</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sorio</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Savarese</surname><given-names>Antonella</given-names></name><xref ref-type="aff" rid="A8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Breda</surname><given-names>Enrico</given-names></name><xref ref-type="aff" rid="A9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Scollo</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="A10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ferro</surname><given-names>Antonella</given-names></name><xref ref-type="aff" rid="A11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tamberi</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="A12"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name><surname>Febbraro</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="A13"><sup>13</sup></xref></contrib><contrib contrib-type="author"><name><surname>Natale</surname><given-names>Donato</given-names></name><xref ref-type="aff" rid="A14"><sup>14</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maio</surname><given-names>Massimo Di</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A16"><sup>16</sup></xref></contrib><contrib contrib-type="author"><name><surname>Califano</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Scognamiglio</surname><given-names>Giosu&#x000e8;</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lorusso</surname><given-names>Domenica</given-names></name><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Canevari</surname><given-names>Silvana</given-names></name><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Losito</surname><given-names>Simona</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gallo</surname><given-names>Ciro</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="author-notes" rid="FN2">**</xref></contrib><contrib contrib-type="author"><name><surname>Pignata</surname><given-names>Sandro</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="author-notes" rid="FN2">**</xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Istituto Nazionale per lo Studio e la Cura dei Tumori - Fondazione G. Pascale, IRCCS, Napoli, Italy</aff><aff id="A2"><sup>2</sup> Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy</aff><aff id="A3"><sup>3</sup> Istituto Oncologico Veneto, IRCCS, Padova, Italy</aff><aff id="A4"><sup>4</sup> Dipartimento di Salute Mentale, Fisica e Medicina Preventiva, Statistica Medica, Seconda Universit&#x000e0;, Napoli, Italy</aff><aff id="A5"><sup>5</sup> Universit&#x000e0; di Napoli Federico II, Napoli, Italy</aff><aff id="A6"><sup>6</sup> Catholic University, Roma, Italy</aff><aff id="A7"><sup>7</sup> Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy</aff><aff id="A8"><sup>8</sup> Istituto Nazionale Tumori Regina Elena, IRCCS, Roma, Italy</aff><aff id="A9"><sup>9</sup> Ospedale S. Giovanni Calibita Fatebenefratelli, Roma, Italy</aff><aff id="A10"><sup>10</sup> Ospedale Cannizzaro, Catania, Italy</aff><aff id="A11"><sup>11</sup> Ospedale S. Chiara, Trento, Italy</aff><aff id="A12"><sup>12</sup> Ospedale Civile, Faenza, Italy</aff><aff id="A13"><sup>13</sup> Ospedale Fatebenefratelli, Benevento, Italy</aff><aff id="A14"><sup>14</sup> Ospedale S. Massimo, Penne (PE), Italy</aff><aff id="A15"><sup>15</sup> Dipartimento di Salute mentale, Fisica e Medicina Preventiva, Anatomia Patologica, Seconda Universit&#x000e0;, Napoli Italy</aff><aff id="A16"><sup>16</sup> Universit&#x000e0; degli Studi, Torino, Italy</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Sandro Pignata,</italic><email>s.pignata@istitutotumori.na.it</email></corresp><fn id="FN1"><label>*</label><p>co-first author</p></fn><fn id="FN2"><label>**</label><p>co-last author</p></fn></author-notes><pub-date pub-type="collection"><day>8</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>15</day><month>9</month><year>2016</year></pub-date><volume>7</volume><issue>45</issue><fpage>72654</fpage><lpage>72661</lpage><history><date date-type="received"><day>11</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>3</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 Perrone et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>No biomarker is available to predict prognosis of patients with advanced ovarian cancer (AOC) and guide the choice of chemotherapy. We performed a prospective-retrospective biomarker study within the MITO2 trial on the treatment of AOC.</p><p>Patients and methods: MITO2 is a randomised multicentre phase 3 trial conducted with 820 AOC patients assigned carboplatin/paclitaxel (carboplatin: AUC5, paclitaxel: 175 mg/m&#x000b2;, every 3 weeks for 6 cycles) or carboplatin/PLD-pegylated liposomal doxorubicin (carboplatin: AUC5, PLD: 30 mg/m&#x000b2;, every 3 weeks for 6 cycles) as first line treatment. Sixteen biomarkers (pathways of adhesion/invasion, apoptosis, transcription regulation, metabolism, and DNA repair) were studied in 229 patients, in a tissue microarray. Progression-free and overall survival were analysed with multivariable Cox model.</p></sec><sec><title>Results</title><p>After 72 months median follow-up, 594 progressions and 426 deaths were reported; there was no significant difference between the two arms in the whole trial. No biomarker had significant prognostic value. Statistically significant interactions with treatment were found for DNA-dependent protein kinase (DNA-PK) and phosphorylated acetyl-coenzymeA carboxylase (pACC), both predicting worse outcome for patients receiving carboplatin/paclitaxel.</p></sec><sec><title>Conclusion</title><p>These data show that in presence of DNA-PK or pACC overexpression, carboplatin/paclitaxel might be less effective than carboplatin/PLD as first line treatment of ovarian cancer patients. Further validation of these findings is warranted.</p></sec></abstract><kwd-group><kwd>ovarian cancer</kwd><kwd>phase 3 clinical trial</kwd><kwd>predictive factors</kwd><kwd>pACC</kwd><kwd>DNA-PK</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Ovarian cancer includes a heterogeneous group of neoplasms, commonly classified according to clinical, morphological and molecular features. [<xref rid="R1" ref-type="bibr">1</xref>] Nevertheless, medical treatment of all types of epithelial ovarian cancer includes carboplatin/paclitaxel as standard backbone, also in combination with bevacizumab. [<xref rid="R2" ref-type="bibr">2</xref>-<xref rid="R4" ref-type="bibr">4</xref>] Therefore, biomarkers able to identify patients who may benefit from standard or alternative chemotherapy might be useful in clinical practice.</p><p>The possibility of grouping ovarian cancer based on molecular portrait has been proposed, [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>] and biochemical and molecular markers have been studied as prognostic or predictive factors. [<xref rid="R7" ref-type="bibr">7</xref>-<xref rid="R9" ref-type="bibr">9</xref>] However, only few immunohistochemistry (IHC) studies have been conducted in large series, through consortia or as meta-analysis. [<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>] Yet, with the exception of BRCA1/2 mutations to guide administration of PARP inhibitors, [<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R13" ref-type="bibr">13</xref>] no biomarker is used in clinical practice.</p><p>In 2011, with a 40 months median follow-up, the MITO2 trial showed that carboplatin/PLD was not superior to carboplatin/paclitaxel as first line treatment of ovarian cancer patients. [<xref rid="R14" ref-type="bibr">14</xref>] Here, with long-term follow up data, we tested the prognostic and/or predictive role of some biomarkers according to a prospective-retrospective design. [<xref rid="R15" ref-type="bibr">15</xref>]</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Long-term efficacy analysis in the whole study population</title><p>After 72 months median follow-up (interquartile range: 60-85), in the whole population of 820 patients, there were 594 events for PFS and 426 events for OS analysis. PFS HR for the carboplatin/PLD <italic>vs</italic> carboplatin/paclitaxel arm was 0.99 (95%CI 0.84-1.17; <italic>p</italic> = 0.93); median PFS was 18 (95%CI 16-23) and 17 months (95%CI 15-19) in the two arms, respectively. OS HR for the carboplatin/PLD <italic>vs</italic> carboplatin/paclitaxel arm was 0.94 (95%CI 0.77-1.13; <italic>p</italic> = 0.49); median OS was 61 (95%CI 51-77) and 53 months (95%CI 42-70) in the two arms, respectively (<xref ref-type="supplementary-material" rid="SD1">Figure S1</xref> online).</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Kaplan-Meier estimated curves of progression-free survival (top) and overall survival (bottom) according to pACC status (negative: graphs on the left, positive: graphs on the right)</title><p>Solid line: carboplatin/paclitaxel; dashed line: carboplatin/PLD. Vertical lines represent censoring.</p></caption><graphic xlink:href="oncotarget-07-72654-g001"/></fig></sec><sec id="s2_2"><title>Biomarker analyses</title><p>Seventeen centres, enrolling 549 patients (67% of the whole study), supplied paraffin blocks from the primary tumor of 258 patients; 28 were excluded because tumor had been collected during interval debulking surgery after initiation of chemotherapy or date of collection was unknown. Therefore, 230 were eligible of whom 229 (42% of patients enrolled in the centres participating to the biomarker study and 28% of the whole study) had at least one biomarker tested and represented the biomarker population (<xref ref-type="supplementary-material" rid="SD1">Figure S2</xref> online).</p><p>The biomarker population was similar to the overall study population, with a slightly lower rate of patients who were not operated at baseline and who had stage IV disease at diagnosis (<xref ref-type="supplementary-material" rid="SD1">Table S2</xref> online). Consistently, both PFS and OS were slightly better in the biomarker population compared to the overall MITO2 population and to all patients enrolled in the centres participating to the biomarker study (<xref ref-type="supplementary-material" rid="SD1">Figure S3</xref> online).</p><p>Distribution of biomarkers by treatment arm is reported in <xref ref-type="supplementary-material" rid="SD1">Table S3</xref> online; due to core losses from the slides during IHC procedure, the number of cases tested ranged from 153 (pAMPK) to 223 (CDK6). No imbalances were observed between treatment arms at the planned significance level of 0.01.</p><p>Moderate pairwise associations (<xref ref-type="supplementary-material" rid="SD1">Table S4</xref> online) were only found between pACC and either DNA-PK (Cramer's V = 0.487, <italic>p</italic> &#x0003c; 0.001) or pAMPK (Cramer's V = 0.433, <italic>p</italic> &#x0003c; 0.001).</p><p>There were no statistically significant associations at the level of 0.001 between patients' or tumors' characteristics and biomarkers' categories (<xref ref-type="supplementary-material" rid="SD1">Tables S5-S23</xref> online) except for DNA-PK and residual disease (<xref ref-type="supplementary-material" rid="SD1">Table S23</xref> online). Univariate PFS and OS Kaplan-Meier curves for each biomarker are depicted in <xref ref-type="supplementary-material" rid="SD1">Figures S4-S41</xref> online.</p><p>No biomarker had statistically significant (predefined significance level of 0.01) prognostic value for PFS and OS at multivariable analyses (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Summary of multivariable analyses with candidate prognostic biomarkers</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><italic>Pathway</italic></th><th align="left" valign="middle" rowspan="1" colspan="1"/><th colspan="2" align="center" valign="middle" rowspan="1">Progression-free survival</th><th colspan="2" align="center" valign="middle" rowspan="1">Overall survival</th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Biomarker</th><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" valign="middle" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold><italic>Adhesion and invasion</italic></bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;ALCAM</td><td align="left" valign="middle" rowspan="1" colspan="1">membrane vs cytoplasm</td><td align="center" valign="middle" rowspan="1" colspan="1">1.16 (0.82-1.66)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.40</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84 (0.52-1.33)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;MCAM</td><td align="left" valign="middle" rowspan="1" colspan="1">positive vs negative</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 (0.65-1.31)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66</td><td align="center" valign="middle" rowspan="1" colspan="1">0.79 (0.50-1.24)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.31</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1">&#x02003;CAV1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Tumor</td><td align="left" valign="middle" rowspan="1" colspan="1">positive vs negative</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90 (0.62-1.32)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.60</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76 (0.45-1.28)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Stroma</td><td align="left" valign="middle" rowspan="1" colspan="1">positive vs negative</td><td align="center" valign="middle" rowspan="1" colspan="1">1.01 (0.75-1.35)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82 (0.56-1.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Claudin3</td><td align="left" valign="middle" rowspan="1" colspan="1">high vs low</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07 (0.77-1.50)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12 (0.73-1.70)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.61</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold><italic>Apoptosis</italic></bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;cFLIP</td><td align="left" valign="middle" rowspan="1" colspan="1">positive vs negative</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97 (0.68-1.40)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.87</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 (0.64-1.58)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;TRAP</td><td align="left" valign="middle" rowspan="1" colspan="1">positive vs negative</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85 (0.60-1.20)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.77 (0.49-1.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;BAG3</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.28</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">2 vs 0-1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.54 (0.91-2.62)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.94 (0.997-3.76)</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">3 vs 0-1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23 (0.80-1.89)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.22 (0.69-2.13)</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold><italic>Transcription regulation</italic></bold></td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1">&#x02003;HOX B13</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Cytoplasmic</td><td align="left" valign="middle" rowspan="1" colspan="1">positive vs negative</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 (0.86-1.69)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07 (0.70-1.64)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Nuclear</td><td align="left" valign="middle" rowspan="1" colspan="1">positive vs negative</td><td align="center" valign="middle" rowspan="1" colspan="1">1.09 (0.80-1.51)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.58</td><td align="center" valign="middle" rowspan="1" colspan="1">1.34 (0.89-2.02)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;HMGA2</td><td align="left" valign="middle" rowspan="1" colspan="1">2/3 vs 0/1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.24 (0.85-1.81)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.26</td><td align="center" valign="middle" rowspan="1" colspan="1">1.32 (0.82-2.10)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1">&#x02003;CDK6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Intensity</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.82</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">high vs low/moderate</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 (0.57-1.35)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.60 (0.35-1.03)</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">very high vs low/moderate</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97 (0.62-1.50)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.94 (0.56-1.58)</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Cellular localization</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.21</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">cytoplasm/membrane vs cytoplasm</td><td align="center" valign="middle" rowspan="1" colspan="1">1.40 (0.94-2.10)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.60 (0.98-2.63)</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">cytoplasm/nucles vs cytoplasm</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86 (0.44-1.65)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.15 (0.52-2.56)</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold><italic>Metabolism</italic></bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Leptin receptor</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.31</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">10%/50% vs &#x0003c;10%</td><td align="center" valign="middle" rowspan="1" colspan="1">1.35 (0.83-2.21)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.98 (1.10-3.56)</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;50% vs &#x0003c;10%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 (0.64-1.31)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.95 (0.59-1.53)</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>At multivariable analyses of putative predictive biomarkers (Table <xref ref-type="table" rid="T2">2</xref>), the predictive value role was confirmed for pACC (for both PFS and OS) and for DNA-PK (only for PFS). In both cases the presence of the biomarker appears to reduce the effect of the carboplatin/paclitaxel combination (Figures <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Summary of multivariable analyses with candidate prognostic and predictive biomarkers</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><italic>Pathway</italic></th><th align="left" valign="middle" rowspan="1" colspan="1"/><th colspan="3" align="center" valign="middle" rowspan="1">Progression-free survival</th><th colspan="3" align="center" valign="middle" rowspan="1">Overall survival</th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Biomarker</th><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" valign="middle" rowspan="1" colspan="1">Interaction <italic>P</italic> value</th><th align="center" valign="middle" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" valign="middle" rowspan="1" colspan="1">Interaction <italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="8" align="left" valign="middle" rowspan="1"><bold>Apoptosis</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;P53</td><td align="left" valign="middle" rowspan="1" colspan="1">high vs low</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71 (0.51-0.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 (0.64-1.58)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59</td></tr><tr><td colspan="8" align="left" valign="middle" rowspan="1"><bold><italic>Metabolism</italic></bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;pAMPK</td><td align="left" valign="middle" rowspan="1" colspan="1">positive vs negative</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 (0.67-1.50)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73</td><td align="center" valign="middle" rowspan="1" colspan="1">1.13 (0.67-1.89)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.65</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;pACC</td><td align="left" valign="middle" rowspan="1" colspan="1">positive vs negative</td><td align="center" valign="middle" rowspan="1" colspan="1">1.15 (0.79-1.68)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.47</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.03</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 (0.77-1.91)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.41</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.005</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;arm: carboplatin/paclitaxel</td><td align="center" valign="middle" rowspan="1" colspan="1">1.79 (1.00-3.20)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.34 (1.20-4.58)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;arm: carboplatin/PLD</td><td align="center" valign="middle" rowspan="1" colspan="1">0.77 (0.45-1.31)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.69 (0.36-1.33)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" valign="middle" rowspan="1"><bold><italic>DNA repair</italic></bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Stathmin</td><td align="left" valign="middle" rowspan="1" colspan="1">high vs neg/moderate intensity</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 (0.62-1.25)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.47</td><td align="center" valign="middle" rowspan="1" colspan="1">0.68</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 (0.55-1.41)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;DNA-PK</td><td align="left" valign="middle" rowspan="1" colspan="1">high vs neg/moderate intensity</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74 (0.52-1.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.10</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.048</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 (0.57-1.35)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;arm: carboplatin/paclitaxel</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12 (0.65-1.95)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;arm: carboplatin/PLD</td><td align="center" valign="middle" rowspan="1" colspan="1">0.51 (0.30-0.86)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>bold <italic>P</italic> values are considered as statistically significant</p></table-wrap-foot></table-wrap><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Kaplan-Meier estimated curves of progression-free survival (top) and overall survival (bottom) according to DNA-PK status (negative/moderate: graphs on the left, high: graphs on the right)</title><p>Solid line: carboplatin/paclitaxel; dashed line: carboplatin/PLD. Vertical lines represent censoring.</p></caption><graphic xlink:href="oncotarget-07-72654-g002"/></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p>We tried to find out molecular tumor characteristics that may ultimately be useful for prognostic prevision and to guide the choice of chemotherapy, within the MITO-2 randomized clinical trial of first-line chemotherapy for patients with AOC. None of 16 putative biomarkers had significant independent prognostic value; the expression of pACC and DNA-PK had a statistically significant interaction with treatment identifying patients who had less benefit from the carboplatin/paclitaxel combination as compared to the carboplatin/PLD one.</p><p>A biomarker analysis performed within a prospective clinical trial, with a common protocol for archival tumor samples management and statistical analysis independent of the laboratories (reducing risk of <italic>ex-post</italic> hypotheses adjustment), has a level of evidence immediately behind that of trials prospectively planned for biomarker analysis. [<xref rid="R15" ref-type="bibr">15</xref>] Nevertheless, our study has <italic>a priori</italic> limitations. First, previous evidence had several weaknesses, deriving from small, retrospective, selected, non-protocol-driven data sets. Second, tumor collection was not mandatory in MITO2, and an attrition bias was expected, that further increased due to random missing data produced by technical limitations of TMA technology; therefore, our study is powered for medium-large prognostic effects. Third, a conservative statistical approach was required to reduce the risk of false positive results coming from multiple testing.</p><p>Two biomarkers, DNA-PK and pACC, had a statistically significant interaction with treatment, their overexpression being predictive of worse efficacy of the carboplatin/paclitaxel treatment. This is consistent with the hypothesis that high DNA-PK expression should identify patients more resistant to paclitaxel therapy. [<xref rid="R16" ref-type="bibr">16</xref>] DNA-PK and pACC expression have different functions, since DNA-PK is the catalytic subunit of a complex necessary for the Non-Homologous End Joining (NHEJ) DNA repair activity, [<xref rid="R17" ref-type="bibr">17</xref>] while ACC is the enzyme that converts acetyl-CoA in malonyl-CoA; the latter is phosphorylated and inhibited by AMP-activated protein kinase (AMPK), a sensor of cellular energy charge and a metabolic master switch. [<xref rid="R18" ref-type="bibr">18</xref>] In the present study, DNA-PK and pACC expression were correlated (Cramer's V = 0.487, <italic>p</italic> &#x0003c; 0.001) and there are at least two likely explanations for this correlation (Figure <xref ref-type="fig" rid="F3">3</xref>). First, DNA-PK could activate both LKB1 and AMPK, resulting in high ACC phosphorylation. [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R19" ref-type="bibr">19</xref>] Second, DNA-PK is a master regulator of fatty acids synthesis and its expression and activity is necessary for the proper regulation of the transcription factors USF1 and SERBP1 that control the expression of ACC and FAS (Fatty Acid Synthase). [<xref rid="R20" ref-type="bibr">20</xref>] In any case, it is now clear that DNA-PK is necessary for several biological functions other than the control of NHEJ DNA-repair and, among these, regulation of cellular metabolism <italic>via</italic> transcription regulation seems to be of primary relevance. [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R21" ref-type="bibr">21</xref>] AMPK also plays an important role in this setting; its activation, indeed, is necessary for the proper induction of doxorubicin-mediated death in several models, possibly through the control of autophagy; [<xref rid="R22" ref-type="bibr">22</xref>, <xref rid="R23" ref-type="bibr">23</xref>] on the contrary, the same mechanism has been shown to protect cells from paclitaxel induced cell death, enhancing glycolysis during mitosis and preventing mitotic cell death. [<xref rid="R24" ref-type="bibr">24</xref>] These data strongly suggest that higher DNA-PK expression can prompt higher AMPK activity, causing higher pACC levels, and ultimately identifies ovarian cancer cells resistant to paclitaxel and sensitive to doxorubicin treatment.</p><p>Alternatively, it should be considered that paclitaxel action on interphase microtubules alters proteins transport and re-localization and may prevent nuclear localization of the enzymes involved in DNA-repair activity including DNA-PK, potentiating the activity of cytotoxic drug like platinum. [<xref rid="R25" ref-type="bibr">25</xref>-<xref rid="R27" ref-type="bibr">27</xref>] It is therefore possible that cells expressing high levels of DNA-PK are less sensitive to paclitaxel-induced DNA-PK cytoplasmic retention and more resistant to the effect of the carboplatin/paclitaxel combination.</p><p>In conclusion, we believe that our findings unveil a new pathway in ovarian cancer that might play an important role in the response of therapy. Additional work is needed to substantiate this hypothesis and to definitely clarify the involved mechanisms; also, further validation in larger series or prospective trials is warranted. DNA-PK and pACC might be first-in-kind biomarkers for personalizing the choice of chemotherapy regimen in ovarian cancer.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Possible molecular links between DNA-PKs and pACC expression</title><p><bold>A.</bold> DNA-PK could phosphorylate and activate AMPK directly, or indirectly <italic>via</italic> LKB1. AMPK activation eventually results in high ACC phosphorylation. <bold>B.</bold> DNA-PK phosphorylates the transcription factor USF1. This event is necessary for the proper expression of FAS (and ACC) by SREBP-1. Higher levels of pACC are in this case the consequence of higher levels of the total protein.</p></caption><graphic xlink:href="oncotarget-07-72654-g003"/></fig></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><p>MITO2 is registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> NCT00326456. Trial details have been previously reported. [<xref rid="R14" ref-type="bibr">14</xref>] In the present long-term efficacy analysis, PFS and OS curves were reported according to the Kaplan-Meier method and were compared with the Log-rank test. Median estimates and HR, with 95% confidence intervals (CI) were also reported. All the analyses were performed according to intention-to-treat.</p><p>Following the approval of study amendments by Ethical Committee and patients' consent, tissue microarrays (TMA), prepared at the Pathology Unit of the NCI Naples (see page 5 online), were sent to seven laboratories involved in the study to test 16 putative biomarkers, some of which had more than one measurement, leading to 19 analyses. Biomarkers were classified according to their prevalent biological activity in 5 different groups: adhesion/invasion, apoptosis, transcription regulation, metabolism, DNA repair. Expected/hypothesized role and evidence or preliminary data for each studied biomarker are detailed online (pages 5-10 online). Methods for biomarker testing procedures are detailed in <xref ref-type="supplementary-material" rid="SD1">Table S1</xref> online. Investigators involved in TMA preparation and analysis were blinded to the assigned treatment and patients' outcome.</p><p>The biomarker population was defined as the subgroup of patients for whom at least one biomarker result was available. Different two-tailed significance levels were applied to different biomarker analyses to partially adjust for multiple comparisons. Three planned conventional levels of P value, more or less conservative, were used according to the specific aim and the number of planned tests (0.001, 0.01, 0.05).</p><p>Baseline characteristics, and PFS and OS outcomes of the biomarker population were described, without statistical testing, to allow an informal comparison with the whole study population and the population of patients enrolled by the centres that participated in tumor block collection.</p><p>Association of biomarkers with baseline characteristics of the patients and the tumors were described and tested with the Chi-square test or the Wilcoxon rank sum test or the Kruskal-Wallis test, as appropriate, using a significance level of 0.001. PFS and OS curves were drawn with the Kaplan-Meier method.</p><p>Biomarkers were categorized in two or more levels according to predefined cut-offs. Pairwise associations between biomarkers were assessed by means of Cramer's V ranging from 0 (no association) to 1 (two variables fully concordant, give the same information). Statistical significance of pairwise associations was assessed with Chi-square test, using a significance level of 0.001.</p><p>The analysis of the prognostic role of each biomarker was adjusted by predefined clinical prognostic factors. Endpoints were PFS and OS. Each biomarker was added to a multivariable Cox's model with treatment arm, stage, residual disease, grading and age as covariates and prognostic effect was tested at a significance level of 0.01.</p><p>For P53, pAMPK, pACC, Stathmin, and DNA-PK previous data suggested a modifying effect on the treatment with taxane/anthracycline (see appendix online). Therefore, a predictive role had to be assessed and it was planned a priori to test the biomarker*treatment interaction, using the conventional significance level of 0.05. If the interaction test was not statistically significant the prognostic effect was evaluated as above.</p></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY MATERIALS FIGURES AND TABLES</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="docx" xlink:href="oncotarget-07-72654-s001.docx" orientation="portrait" xlink:type="simple" id="d35e1266" position="anchor"/></supplementary-material></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>The Authors have declared no conflict of interest.</p></fn><fn fn-type="supported-by"><p><bold>FUNDING</bold></p><p>This work was partially supported by Integrated Therapeutics Group Schering-Plough Italy; AIRC (Italian Association for Cancer Research) grant IG5776; Ministero della Salute (RF-2010-2309704). The supporters did not play any role in protocol and manuscript writing, trial conduction, data analysis and interpretation. The study was sponsored by National Cancer Institute of Naples.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurman</surname><given-names>RJ</given-names></name><name><surname>Shih Ie</surname><given-names>M</given-names></name></person-group><article-title>Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer&#x02014;shifting the paradigm</article-title><source>Human pathology</source><year>2011</year><volume>42</volume><fpage>918</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">21683865</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>RA</given-names></name><name><surname>Brady</surname><given-names>MF</given-names></name><name><surname>Bookman</surname><given-names>MA</given-names></name><name><surname>Fleming</surname><given-names>GF</given-names></name><name><surname>Monk</surname><given-names>BJ</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Mannel</surname><given-names>RS</given-names></name><name><surname>Homesley</surname><given-names>HD</given-names></name><name><surname>Fowler</surname><given-names>J</given-names></name><name><surname>Greer</surname><given-names>BE</given-names></name><name><surname>Boente</surname><given-names>M</given-names></name><name><surname>Birrer</surname><given-names>MJ</given-names></name><name><surname>Liang</surname><given-names>SX</given-names></name><name><surname>Gynecologic Oncology</surname><given-names>G</given-names></name></person-group><article-title>Incorporation of bevacizumab in the primary treatment of ovarian cancer</article-title><source>The New England journal of medicine</source><year>2011</year><volume>365</volume><fpage>2473</fpage><lpage>2483</lpage><pub-id pub-id-type="pmid">22204724</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perren</surname><given-names>TJ</given-names></name><name><surname>Swart</surname><given-names>AM</given-names></name><name><surname>Pfisterer</surname><given-names>J</given-names></name><name><surname>Ledermann</surname><given-names>JA</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><name><surname>Kristensen</surname><given-names>G</given-names></name><name><surname>Carey</surname><given-names>MS</given-names></name><name><surname>Beale</surname><given-names>P</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Kurzeder</surname><given-names>C</given-names></name><name><surname>du Bois</surname><given-names>A</given-names></name><name><surname>Sehouli</surname><given-names>J</given-names></name><name><surname>Kimmig</surname><given-names>R</given-names></name><name><surname>Stahle</surname><given-names>A</given-names></name><name><surname>Collinson</surname><given-names>F</given-names></name><name><surname>Essapen</surname><given-names>S</given-names></name><etal/></person-group><article-title>A phase 3 trial of bevacizumab in ovarian cancer</article-title><source>The New England journal of medicine</source><year>2011</year><volume>365</volume><fpage>2484</fpage><lpage>2496</lpage><pub-id pub-id-type="pmid">22204725</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thigpen</surname><given-names>T</given-names></name><name><surname>duBois</surname><given-names>A</given-names></name><name><surname>McAlpine</surname><given-names>J</given-names></name><name><surname>DiSaia</surname><given-names>P</given-names></name><name><surname>Fujiwara</surname><given-names>K</given-names></name><name><surname>Hoskins</surname><given-names>W</given-names></name><name><surname>Kristensen</surname><given-names>G</given-names></name><name><surname>Mannel</surname><given-names>R</given-names></name><name><surname>Markman</surname><given-names>M</given-names></name><name><surname>Pfisterer</surname><given-names>J</given-names></name><name><surname>Quinn</surname><given-names>M</given-names></name><name><surname>Reed</surname><given-names>N</given-names></name><name><surname>Swart</surname><given-names>AM</given-names></name><name><surname>Berek</surname><given-names>J</given-names></name><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Freyer</surname><given-names>G</given-names></name><etal/></person-group><article-title>First-line therapy in ovarian cancer trials</article-title><source>International journal of gynecological cancer</source><year>2011</year><volume>21</volume><fpage>756</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">21543937</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bookman</surname><given-names>MA</given-names></name><name><surname>Gilks</surname><given-names>CB</given-names></name><name><surname>Kohn</surname><given-names>EC</given-names></name><name><surname>Kaplan</surname><given-names>KO</given-names></name><name><surname>Huntsman</surname><given-names>D</given-names></name><name><surname>Aghajanian</surname><given-names>C</given-names></name><name><surname>Birrer</surname><given-names>MJ</given-names></name><name><surname>Ledermann</surname><given-names>JA</given-names></name><name><surname>Oza</surname><given-names>AM</given-names></name><name><surname>Swenerton</surname><given-names>KD</given-names></name></person-group><article-title>Better therapeutic trials in ovarian cancer</article-title><source>Journal of the National Cancer Institute</source><year>2014</year><volume>106</volume><fpage>dju029</fpage><pub-id pub-id-type="pmid">24627272</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohn</surname><given-names>EC</given-names></name><name><surname>Romano</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name></person-group><article-title>Clinical implications of using molecular diagnostics for ovarian cancers</article-title><source>Annals of oncology</source><year>2013</year><volume>24</volume><issue>Suppl 10</issue><fpage>x22</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">24265398</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Graeff</surname><given-names>P</given-names></name><name><surname>Crijns</surname><given-names>AP</given-names></name><name><surname>de Jong</surname><given-names>S</given-names></name><name><surname>Boezen</surname><given-names>M</given-names></name><name><surname>Post</surname><given-names>WJ</given-names></name><name><surname>de Vries</surname><given-names>EG</given-names></name><name><surname>van der Zee</surname><given-names>AG</given-names></name><name><surname>de Bock</surname><given-names>GH</given-names></name></person-group><article-title>Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis</article-title><source>British journal of cancer</source><year>2009</year><volume>101</volume><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">19513073</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>M</given-names></name></person-group><article-title>Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis</article-title><source>Tumour biology</source><year>2014</year><volume>35</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">23873100</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies</article-title><source>Journal of cancer research and clinical oncology</source><year>2013</year><volume>139</volume><fpage>1257</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">23595127</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobel</surname><given-names>M</given-names></name><name><surname>Madore</surname><given-names>J</given-names></name><name><surname>Ramus</surname><given-names>SJ</given-names></name><name><surname>Clarke</surname><given-names>BA</given-names></name><name><surname>Pharoah</surname><given-names>PD</given-names></name><name><surname>Deen</surname><given-names>S</given-names></name><name><surname>Bowtell</surname><given-names>DD</given-names></name><name><surname>Odunsi</surname><given-names>K</given-names></name><name><surname>Menon</surname><given-names>U</given-names></name><name><surname>Morrison</surname><given-names>C</given-names></name><name><surname>Lele</surname><given-names>S</given-names></name><name><surname>Bshara</surname><given-names>W</given-names></name><name><surname>Sucheston</surname><given-names>L</given-names></name><name><surname>Beckmann</surname><given-names>MW</given-names></name><name><surname>Hein</surname><given-names>A</given-names></name><name><surname>Thiel</surname><given-names>FC</given-names></name><etal/></person-group><article-title>Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study</article-title><source>British journal of cancer</source><year>2014</year><volume>111</volume><fpage>2297</fpage><lpage>2307</lpage><pub-id pub-id-type="pmid">25349970</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieh</surname><given-names>W</given-names></name><name><surname>Kobel</surname><given-names>M</given-names></name><name><surname>Longacre</surname><given-names>TA</given-names></name><name><surname>Bowtell</surname><given-names>DD</given-names></name><name><surname>deFazio</surname><given-names>A</given-names></name><name><surname>Goodman</surname><given-names>MT</given-names></name><name><surname>Hogdall</surname><given-names>E</given-names></name><name><surname>Deen</surname><given-names>S</given-names></name><name><surname>Wentzensen</surname><given-names>N</given-names></name><name><surname>Moysich</surname><given-names>KB</given-names></name><name><surname>Brenton</surname><given-names>JD</given-names></name><name><surname>Clarke</surname><given-names>BA</given-names></name><name><surname>Menon</surname><given-names>U</given-names></name><name><surname>Gilks</surname><given-names>CB</given-names></name><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Madore</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study</article-title><source>The Lancet Oncology</source><year>2013</year><volume>14</volume><fpage>853</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">23845225</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaye</surname><given-names>SB</given-names></name><name><surname>Lubinski</surname><given-names>J</given-names></name><name><surname>Matulonis</surname><given-names>U</given-names></name><name><surname>Ang</surname><given-names>JE</given-names></name><name><surname>Gourley</surname><given-names>C</given-names></name><name><surname>Karlan</surname><given-names>BY</given-names></name><name><surname>Amnon</surname><given-names>A</given-names></name><name><surname>Bell-McGuinn</surname><given-names>KM</given-names></name><name><surname>Chen</surname><given-names>LM</given-names></name><name><surname>Friedlander</surname><given-names>M</given-names></name><name><surname>Safra</surname><given-names>T</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Wickens</surname><given-names>M</given-names></name><name><surname>Lowe</surname><given-names>ES</given-names></name><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>Kaufman</surname><given-names>B</given-names></name></person-group><article-title>Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer</article-title><source>Journal of clinical oncology</source><year>2012</year><volume>30</volume><fpage>372</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">22203755</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledermann</surname><given-names>J</given-names></name><name><surname>Harter</surname><given-names>P</given-names></name><name><surname>Gourley</surname><given-names>C</given-names></name><name><surname>Friedlander</surname><given-names>M</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Rustin</surname><given-names>G</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Meier</surname><given-names>W</given-names></name><name><surname>Shapira-Frommer</surname><given-names>R</given-names></name><name><surname>Safra</surname><given-names>T</given-names></name><name><surname>Matei</surname><given-names>D</given-names></name><name><surname>Fielding</surname><given-names>A</given-names></name><name><surname>Spencer</surname><given-names>S</given-names></name><name><surname>Dougherty</surname><given-names>B</given-names></name><name><surname>Orr</surname><given-names>M</given-names></name><name><surname>Hodgson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial</article-title><source>The Lancet Oncology</source><year>2014</year><volume>15</volume><fpage>852</fpage><lpage>861</lpage><pub-id pub-id-type="pmid">24882434</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pignata</surname><given-names>S</given-names></name><name><surname>Scambia</surname><given-names>G</given-names></name><name><surname>Ferrandina</surname><given-names>G</given-names></name><name><surname>Savarese</surname><given-names>A</given-names></name><name><surname>Sorio</surname><given-names>R</given-names></name><name><surname>Breda</surname><given-names>E</given-names></name><name><surname>Gebbia</surname><given-names>V</given-names></name><name><surname>Musso</surname><given-names>P</given-names></name><name><surname>Frigerio</surname><given-names>L</given-names></name><name><surname>Del Medico</surname><given-names>P</given-names></name><name><surname>Lombardi</surname><given-names>AV</given-names></name><name><surname>Febbraro</surname><given-names>A</given-names></name><name><surname>Scollo</surname><given-names>P</given-names></name><name><surname>Ferro</surname><given-names>A</given-names></name><name><surname>Tamberi</surname><given-names>S</given-names></name><name><surname>Brandes</surname><given-names>A</given-names></name><etal/></person-group><article-title>Carboplatin plus paclitaxel <italic>versus</italic> carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial</article-title><source>Journal of clinical oncology</source><year>2011</year><volume>29</volume><fpage>3628</fpage><lpage>3635</lpage><pub-id pub-id-type="pmid">21844495</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>RM</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name></person-group><article-title>Use of archived specimens in evaluation of prognostic and predictive biomarkers</article-title><source>J Natl Cancer Inst</source><year>2009</year><volume>101</volume><fpage>1446</fpage><lpage>1452</lpage><pub-id pub-id-type="pmid">19815849</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonego</surname><given-names>M</given-names></name><name><surname>Schiappacassi</surname><given-names>M</given-names></name><name><surname>Lovisa</surname><given-names>S</given-names></name><name><surname>Dall'Acqua</surname><given-names>A</given-names></name><name><surname>Bagnoli</surname><given-names>M</given-names></name><name><surname>Lovat</surname><given-names>F</given-names></name><name><surname>Libra</surname><given-names>M</given-names></name><name><surname>D'Andrea</surname><given-names>S</given-names></name><name><surname>Canzonieri</surname><given-names>V</given-names></name><name><surname>Militello</surname><given-names>L</given-names></name><name><surname>Napoli</surname><given-names>M</given-names></name><name><surname>Giorda</surname><given-names>G</given-names></name><name><surname>Pivetta</surname><given-names>B</given-names></name><name><surname>Mezzanzanica</surname><given-names>D</given-names></name><name><surname>Barbareschi</surname><given-names>M</given-names></name><name><surname>Valeri</surname><given-names>B</given-names></name><etal/></person-group><article-title>Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer</article-title><source>EMBO molecular medicine</source><year>2013</year><volume>5</volume><fpage>707</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">23610071</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>JF</given-names></name><name><surname>Knudsen</surname><given-names>KE</given-names></name></person-group><article-title>Beyond DNA repair: DNA-PK function in cancer</article-title><source>Cancer Discov</source><year>2014</year><volume>4</volume><fpage>1126</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">25168287</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardie</surname><given-names>DG</given-names></name><name><surname>Ross</surname><given-names>FA</given-names></name><name><surname>Hawley</surname><given-names>SA</given-names></name></person-group><article-title>AMPK: a nutrient and energy sensor that maintains energy homeostasis</article-title><source>Nature reviews Molecular cell biology</source><year>2012</year><volume>13</volume><fpage>251</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">22436748</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanli</surname><given-names>T</given-names></name><name><surname>Steinberg</surname><given-names>GR</given-names></name><name><surname>Singh</surname><given-names>G</given-names></name><name><surname>Tsakiridis</surname><given-names>T</given-names></name></person-group><article-title>AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway</article-title><source>Cancer biology &#x00026; therapy</source><year>2014</year><volume>15</volume><fpage>156</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">24100703</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>RH</given-names></name><name><surname>Chang</surname><given-names>I</given-names></name><name><surname>Hudak</surname><given-names>CS</given-names></name><name><surname>Hyun</surname><given-names>S</given-names></name><name><surname>Kwan</surname><given-names>HY</given-names></name><name><surname>Sul</surname><given-names>HS</given-names></name></person-group><article-title>A role of DNA-PK for the metabolic gene regulation in response to insulin</article-title><source>Cell</source><year>2009</year><volume>136</volume><fpage>1056</fpage><lpage>1072</lpage><pub-id pub-id-type="pmid">19303849</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>JF</given-names></name><name><surname>Kothari</surname><given-names>V</given-names></name><name><surname>Drake</surname><given-names>JM</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Dylgjeri</surname><given-names>E</given-names></name><name><surname>Dean</surname><given-names>JL</given-names></name><name><surname>Schiewer</surname><given-names>MJ</given-names></name><name><surname>McNair</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>JK</given-names></name><name><surname>Aytes</surname><given-names>A</given-names></name><name><surname>Magee</surname><given-names>MS</given-names></name><name><surname>Snook</surname><given-names>AE</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Den</surname><given-names>RB</given-names></name><name><surname>Birbe</surname><given-names>RC</given-names></name><name><surname>Gomella</surname><given-names>LG</given-names></name><etal/></person-group><article-title>DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis</article-title><source>Cancer Cell</source><year>2015</year><volume>28</volume><fpage>97</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">26175416</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>YL</given-names></name><name><surname>He</surname><given-names>SH</given-names></name><name><surname>Miao</surname><given-names>DS</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Bi</surname><given-names>ZG</given-names></name></person-group><article-title>Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>6557</fpage><lpage>6568</lpage><pub-id pub-id-type="pmid">20802518</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>DH</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name></person-group><article-title>SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin</article-title><source>Cancer research</source><year>2014</year><volume>74</volume><fpage>298</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">24240701</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domenech</surname><given-names>E</given-names></name><name><surname>Maestre</surname><given-names>C</given-names></name><name><surname>Esteban-Martinez</surname><given-names>L</given-names></name><name><surname>Partida</surname><given-names>D</given-names></name><name><surname>Pascual</surname><given-names>R</given-names></name><name><surname>Fernandez-Miranda</surname><given-names>G</given-names></name><name><surname>Seco</surname><given-names>E</given-names></name><name><surname>Campos-Olivas</surname><given-names>R</given-names></name><name><surname>Perez</surname><given-names>M</given-names></name><name><surname>Megias</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>K</given-names></name><name><surname>Lopez</surname><given-names>M</given-names></name><name><surname>Saha</surname><given-names>AK</given-names></name><name><surname>Velasco</surname><given-names>G</given-names></name><name><surname>Rial</surname><given-names>E</given-names></name><name><surname>Mendez</surname><given-names>R</given-names></name><etal/></person-group><article-title>AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest</article-title><source>Nat Cell Biol</source><year>2015</year><volume>17</volume><fpage>1304</fpage><lpage>1316</lpage><pub-id pub-id-type="pmid">26322680</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komlodi-Pasztor</surname><given-names>E</given-names></name><name><surname>Sackett</surname><given-names>D</given-names></name><name><surname>Wilkerson</surname><given-names>J</given-names></name><name><surname>Fojo</surname><given-names>T</given-names></name></person-group><article-title>Mitosis is not a key target of microtubule agents in patient tumors</article-title><source>Nat Rev Clin Oncol</source><year>2011</year><volume>8</volume><fpage>244</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">21283127</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchison</surname><given-names>TJ</given-names></name></person-group><article-title>The proliferation rate paradox in antimitotic chemotherapy</article-title><source>Mol Biol Cell</source><year>2012</year><volume>23</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">22210845</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Poruchynsky</surname><given-names>MS</given-names></name><name><surname>Komlodi-Pasztor</surname><given-names>E</given-names></name><name><surname>Trostel</surname><given-names>S</given-names></name><name><surname>Wilkerson</surname><given-names>J</given-names></name><name><surname>Regairaz</surname><given-names>M</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Kumar Maity</surname><given-names>T</given-names></name><name><surname>Robey</surname><given-names>R</given-names></name><name><surname>Burotto</surname><given-names>M</given-names></name><name><surname>Sackett</surname><given-names>D</given-names></name><name><surname>Guha</surname><given-names>U</given-names></name><name><surname>Fojo</surname><given-names>AT</given-names></name></person-group><article-title>Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins</article-title><conf-name>Proceedings of the National Academy of Sciences of the United States of America</conf-name><year>2015</year><volume>112</volume><fpage>1571</fpage><lpage>1576</lpage></element-citation></ref></ref-list></back></article>